AML Therapy With Irradiated Allogeneic Cells | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02105116

AML Therapy With Irradiated Allogeneic Cells
For more details on this clinical trial, including contact information, please see this trial’s listing on

This pilot clinical trial studies if cells donated by a close genetic relative can help keep acute myeloid leukemia (AML) from coming back after standard chemotherapy induces a complete remission. Blood cells obtained from a donor include a variety of blood cells that may trigger the patient's immune system to react against AML cells.

Study Date: 
Sat, 02/01/2014 to Tue, 01/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Drug: fludarabine phosphate Given IV Other Names: 2-F-ara-AMP Beneflur Fludara Drug: cytarabine Given IV Other Names: ARA-C arabinofuranosylcytosine arabinosylcytosine Cytosar-U cytosine arabinoside Biological: donor lymphocytes Undergo infusion of donor lymphocytes Other: laboratory biomarker analysis Correlative studies Drug: G-CSF Given IV Other Names: Filgrastim Neupogen®